Carolyn Davidson
Psychiatric/Mental Health · Milwaukee, WINPI 1043440480
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,375 of the $45,784 with a category attached, or 72.9%. AbbVie accounts for 66.7% of it on its own, with 26 other manufacturers making up the rest. Among psychiatric/mental health clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 595 payments — averaging $76.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$31K
- Teva Pharmaceuticals USA, Inc.$6K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Takeda Pharmaceuticals U.S.A., Inc.$946
- Axsome Therapeutics, Inc.$862
- plus $5K from 21 others
What the payments were for
- Speaking & faculty fees$33,37573%
- Travel & lodging$4371%
- Food & beverage$11,76826%
- Education$2040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 138 | $30,515 |
| Teva Pharmaceuticals USA, Inc. | 37 | $6,305 |
| Alkermes, Inc. | 55 | $1,199 |
| Otsuka America Pharmaceutical, Inc. | 44 | $1,191 |
| Takeda Pharmaceuticals U.S.A., Inc. | 56 | $946 |
| Axsome Therapeutics, Inc. | 31 | $862 |
| Neurocrine Biosciences, Inc. | 28 | $718 |
| Vanda Pharmaceuticals Inc. | 44 | $700 |
| Corium, LLC | 28 | $520 |
| Lundbeck LLC | 27 | $477 |
| Supernus Pharmaceuticals, Inc. | 18 | $414 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $393 |
| Almatica Pharma LLC | 21 | $386 |
| Johnson & Johnson | 9 | $267 |
| Ironshore Pharmaceuticals Inc. | 10 | $195 |
| Adlon Therapeutics L.p. | 7 | $123 |
| Idorsia Pharmaceuticals US Inc | 5 | $92 |
| Collegium Pharmaceutical, Inc. | 4 | $81 |
| Neos Therapeutics, LP | 4 | $80 |
| Bausch Health US, LLC | 4 | $73 |
| Tris Pharma Inc | 4 | $68 |
| Jazz Pharmaceuticals Inc. | 2 | $38 |
| Sage Therapeutics, LLC | 2 | $37 |
| Indivior Inc. | 2 | $35 |
| Merck | 2 | $29 |
| USWM, LLC | 1 | $24 |
| Biogen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$28,755
- UZEDY$5,417
- LYBALVI$979
- Austedo XR$507
- Auvelity$490
- ARISTADA$477
- NUEDEXTA$125
- Fanapt$125
- ABILIFY ASIMTUFII$122
- ABILIFY MAINTENA$122
- INGREZZA$120
- ARISTADA INITIO$119
- INVEGA SUSTENNA$113
- QELBREE$110
- CAPLYTA$109
How this compares
$45,784 in reported general payments places this provider in the 95th percentile of 384 psychiatric/mental health providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 119 | $185,293 |
| AustedoDeutetrabenazine | 18 | $132,642 |
| CaplytaLumateperone Tosylate | 17 | $42,487 |
| TrintellixVortioxetine Hydrobromide | 52 | $30,230 |
| VyvanseLisdexamfetamine Dimesylate | 31 | $13,383 |
| Risperidone ErRisperidone Microspheres | 12 | $11,774 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 186 | $6,460 |
| Aripiprazole | 165 | $6,304 |
| Lisdexamfetamine Dimesylate | 27 | $5,164 |
| Duloxetine Hcl | 182 | $4,315 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 45 | $3,657 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 76 | $3,637 |
| Bupropion XlBupropion Hcl | 204 | $3,634 |
| Hydroxyzine Hcl | 137 | $3,526 |
| Clozapine | 15 | $2,846 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $30,515 | $185,293119 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $6,305 | $132,64218 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $946 | $43,61383 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $393 | $42,48717 claims |
| Almatica Pharma LLCSertraline Hcl | $386 | $1,538149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 384 psychiatric/mental health providers in Wisconsin.
Other psychiatric/mental health in Milwaukee
- Sherry AleksichMilwaukee$33K
- Ngozi ObioraMilwaukee$19K
- Victoria McGinleyMilwaukee$9K
- Andrea MitchellMilwaukee$6K
- Angeline VercauterenMilwaukee$6K
- Lisa CwiklaMilwaukee$5K
- Julia JasterMilwaukee$5K
- Angelia Felton-WilksMilwaukee$4K
- Kristen AndersonMilwaukee$4K
- Julianne JohnMilwaukee$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.